CAJ | 학술논문

目的研究吉非替尼对晚期非小细胞肺癌的治疗效果。方法选取某院2011年2月～2012年2月收治的期非小细胞肺癌,不能耐受化疗或化疗失败的晚期NSCLC患者78例为研究对象,给予患者每日口服250mg吉非替尼1次,服药1个月以上至病情进展为止,观察吉非替尼的疗效以及出现的不良反应。结果78例患者中经治疗完全缓解4例,部分缓解22例.稳定25例,进展27例.有效率33.3%,疾病控制率65.4%中位肿瘤(TTP)进展时间为3.8月,1年生存几率为44.9%,36例患者出现皮疹,8例患者出现恶心21例患者出现腹泻.22例患者出现皮肤干燥,3例出现转氨酶上升。结论吉非替尼对于晚期 NSCLC具有一定疗效,其不良反应较轻,容易被患者接受,可作为多次化疗失败以及不耐受患者首选药物治疗.
목적연구길비체니대만기비소세포폐암적치료효과。방법선취모원2011년2월～2012년2월수치적기비소세포폐암,불능내수화료혹화료실패적만기NSCLC환자78례위연구대상,급여환자매일구복250mg길비체니1차,복약1개월이상지병정진전위지,관찰길비체니적료효이급출현적불량반응。결과78례환자중경치료완전완해4례,부분완해22례.은정25례,진전27례.유효솔33.3%,질병공제솔65.4%중위종류(TTP)진전시간위3.8월,1년생존궤솔위44.9%,36례환자출현피진,8례환자출현악심21례환자출현복사.22례환자출현피부간조,3례출현전안매상승。결론길비체니대우만기 NSCLC구유일정료효,기불량반응교경,용역피환자접수,가작위다차화료실패이급불내수환자수선약물치료.
Objective To study the gefitinib in advanced non smal cel lung cancer treatment. Methods From 2011 February to 2012 February were non-smal cel lung cancer, cannot tolerate chemotherapy or chemotherapy advanced NSCLC patients 78 patients as the research object, giving patients a daily oral 250mg gefitinib than once, more than a month of medication to patients, observation of Ji not adverse reaction and the ef ect of imatinib. Results In the 78 patients after treatment, 4 cases of complete remission, partial remission in 22 cases. 25 cases of stable, progress in 27 cases. The ef iciency of 33.3%, disease control rate of 65.4%in tumor (TTP) of time for 3.8 months, 1 year survival rate was 44.9%, 36 cases of patients with skin rash, 8 patients had nausea and diarrhea occurred in 21 patients who.22 patients with dry skin, 3 cases with transaminase increased. Conclusion Than gefitinib in advanced NSCLC has certain curative ef ect, adverse reaction is light, easy to be accepted by patients, can be used as many times of failure in chemotherapy and intolerance of choice for patients with drug therapy.